Risperidone extended release - Luye Pharma Group
Alternative Names: LY-03004; Risperidone ER microspheres - Luye Pharma Group; Risperidone Microspheres for Injection (II) - Luye Pharma Group; RykindoLatest Information Update: 07 Sep 2023
At a glance
- Originator Luye Pharma Group
- Class Antidepressants; Antineoplastics; Antipsychotics; Behavioural disorder therapies; Fluorinated hydrocarbons; Isoxazoles; Mood stabilisers; Piperidines; Pyrimidinones; Small molecules
- Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 5-HT2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Schizophrenia
- Registered Bipolar disorders
Most Recent Events
- 07 Sep 2023 Phase-II clinical trials in Bipolar disorders in Europe (IM) prior to September 2023 (Luye Pharma pipeline, September 2023)
- 07 Sep 2023 Phase-II clinical trials in Schizophrenia in Europe (IM) prior to September 2023 (Luye Pharma pipeline, September 2023)
- 15 Jan 2023 Registered for Bipolar disorders (Adjunctive treatment) in USA (IM)